- Home
- NIXX vs BCAB Comparison
NIXX vs BCAB Comparison
Compare NIXX & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIXX
- BCAB
- Stock Information
- Founded
- NIXX 2010
- BCAB 2007
- Country
- NIXX United States
- BCAB United States
- Employees
- NIXX N/A
- BCAB N/A
- Industry
- NIXX
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- NIXX
- BCAB Health Care
- Exchange
- NIXX NYSE
- BCAB Nasdaq
- Market Cap
- NIXX 28.7M
- BCAB 27.0M
- IPO Year
- NIXX N/A
- BCAB 2020
- Fundamental
- Price
- NIXX $1.73
- BCAB $0.35
- Analyst Decision
- NIXX
- BCAB Buy
- Analyst Count
- NIXX 0
- BCAB 2
- Target Price
- NIXX N/A
- BCAB $1.00
- AVG Volume (30 Days)
- NIXX 529.2K
- BCAB 612.0K
- Earning Date
- NIXX 05-14-2025
- BCAB 03-27-2025
- Dividend Yield
- NIXX N/A
- BCAB N/A
- EPS Growth
- NIXX N/A
- BCAB N/A
- EPS
- NIXX N/A
- BCAB N/A
- Revenue
- NIXX $612,046.00
- BCAB $11,000,000.00
- Revenue This Year
- NIXX $209.13
- BCAB N/A
- Revenue Next Year
- NIXX N/A
- BCAB N/A
- P/E Ratio
- NIXX N/A
- BCAB N/A
- Revenue Growth
- NIXX N/A
- BCAB N/A
- 52 Week Low
- NIXX $1.20
- BCAB $0.24
- 52 Week High
- NIXX $8.50
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- NIXX N/A
- BCAB 44.62
- Support Level
- NIXX N/A
- BCAB $0.28
- Resistance Level
- NIXX N/A
- BCAB $0.40
- Average True Range (ATR)
- NIXX 0.00
- BCAB 0.04
- MACD
- NIXX 0.00
- BCAB 0.01
- Stochastic Oscillator
- NIXX 0.00
- BCAB 60.00
About NIXX NIXXY INC
Nixxy Inc formerly Recruiter.Com Group Inc is a hiring platform for the network of recruiters. It empowers businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology. The Recruiter.com network of over 28,000 small and independent recruiters utilize a web platform, complete with AI-driven job matching, to recruit talent faster. Its Recruiters On Demand provides businesses of all sizes access to virtual recruiters specialized by vertical industries to source, engage, and hire talent on an as-needed basis.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.